Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Decreased Expression of Sema3a, an Immune Modulator, in Blood Sample of Multiple Sclerosis Patients Publisher Pubmed

Summary: Lower Sema3A expression & serum levels in RRMS patients suggest its role as a potential diagnostic biomarker. #MultipleSclerosis #Sema3A

Rezaeepoor M1 ; Shapoori S1 ; Ganjalikhanihakemi M1 ; Etemadifar M2 ; Alsahebfosoul F1 ; Eskandari N1 ; Mansourian M3
Authors

Source: Gene Published:2017


Abstract

Semaphorin 3A (Sema3A) as an immune modulator could participate in the pathogenesis of autoimmune diseases. In the current study, we aimed to investigate Sema3A expression in peripheral blood mononuclear cells (PBMCs) and its serum level in relapsing-remitting multiple sclerosis (RRMS) patients. Fifteen newly determined and untreated RRMS patients were chosen and assessed in relapsing and remitting phases in compare with fifteen healthy individuals. In consistent with previous findings in other autoimmune diseases, our results revealed that serum level of Sema3A and its expression in PBMCs of RRMS patients were significantly lower than in normal subjects. We also evaluated this down regulation predictive value with ROC analysis. According to our data, we suggest that Sema3A could be involved in pathogenesis of MS and might be a potential diagnostic biomarker for the disease. © 2017 Elsevier B.V.
Other Related Docs
5. Serum Level of Interleukin 36 in Patients With Multiple Sclerosis, Journal of Immunoassay and Immunochemistry (2018)
8. A Novel Approach to Discriminate Subgroups in Multiple Sclerosis, Iranian Journal of Allergy, Asthma and Immunology (2016)